UroGen Pharma Ltd. (LON:0XOD)
United Kingdom · Delayed Price · Currency is GBP · Price in USD | Market Cap | 974.92M +18.0% |
| Revenue (ttm) | 188.50M +159.3% |
| Net Income | -49.53M |
| EPS | -0.98 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 11.20 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 47 |
| Open | 26.86 |
| Previous Close | 25.90 |
| Day's Range | 26.00 - 26.86 |
| 52-Week Range | 16.19 - 51.11 |
| Beta | 1.64 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About UroGen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocal... [Read more]
Financial Performance
In 2025, UroGen Pharma's revenue was $109.79 million, an increase of 21.45% compared to the previous year's $90.40 million. Losses were -$153.49 million, 21.0% more than in 2024.
Financial numbers in USD Financial StatementsNews
UroGen Pharma Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
ZUSDURI adoption is broadening, with management retaining a $1bn-plus peak-sales view and a 4–5-year launch trajectory. Pipeline expansion and a dedicated JELMYTO team support longer-term growth; Q4 profitability and positive cash flow are expected.
UroGen Pharma price target lowered to $62 from $65 at Ladenburg
Ladenburg lowered the firm’s price target on UroGen Pharma (URGN) to $62 from $65 and keeps a Buy rating on the shares. The firm would be buyers of UroGen following…
UroGen Pharma price target lowered to $56 from $58 at Guggenheim
Guggenheim analyst Michael Schmidt lowered the firm’s price target on UroGen Pharma (URGN) to $56 from $58 and keeps a Buy rating on the shares.
UroGen Pharma Earnings Call Transcript: Q3 2026
ZUSDURI revenue reached $68M, up 35% QoQ, and total revenue was $89M. Management expects Q4 profitability and positive cash flow, while JELMYTO faces clinical-trial headwinds and UGN-103 advances toward a 2027 FDA decision.
UroGen Pharma Earnings release: Q3 2026
UroGen Pharma released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
UroGen Pharma Quarterly report: Q3 2026
UroGen Pharma has published its Q3 2026 quarterly earnings report on November 4, 2026.
UroGen Pharma reports Q3 EPS (3c), consensus 10c
Reports Q3 revenue $89M, consensus $89.91M. “We delivered another strong quarter of execution, with ZUSDURI continuing to scale as growing repeat utilization, expanding community adoption, and broader...
UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights
ZUSDURI ® generated $68.0 million in revenue in the third quarter of 2026, representing 35% quarter-over-quarter growth The FDA accepted UroGen's NDA for UGN-103 (next-generation novel mitomycin-based...
UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
PRINCETON, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
Phase 1 clinical trial to evaluate local intravesical administration of UGN-501 UGN-501 is a differentiated investigational next-generation oncolytic virus designed to combine direct tumor cell destru...
UroGen's Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer
Five-year Olympus follow-up data published in Therapeutic Advances in Urology reinforce the long-term durability of response with JELMYTO Results demonstrate sustained disease control through extended...
UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026
Conference Call and Webcast Scheduled for Wednesday, November 4th, 2026, at 10:00 AM ET Conference Call and Webcast Scheduled for Wednesday, November 4th, 2026, at 10:00 AM ET
UroGen Pharma announces FDA acceptance of UGN-103 NDA
UroGen Pharma (URGN) announced FDA acceptance of the new drug application, or NDA, for investigational drug UGN-103 for intravesical solution for the treatment of adults with recurrent low-grade inter...
UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC
PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and speci...
UroGen Pharma management to meet with Oppenheimer
Meeting to be held in San Francisco on October 20, in Los Angeles on October 21-22 and Denver on October 23 hosted by Oppenheimer.
UroGen Pharma falls -12.8%
UroGen Pharma (URGN) is down -12.8%, or -$5.20 to $35.50.
UroGen Pharma management to meet with Piper Sandler
Meeting to be held on September 28-30 hosted by Piper Sandler.
UroGen Pharma Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The discussion highlighted strong early demand for Zusduri, with significant room for physician adoption and growth, especially in community settings. Key pipeline milestones include UGN-103's upcoming data and approval, UGN-104's trial progress, and the initiation of UGN-501 studies, supporting long-term expansion.
UroGen Pharma Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
RTGel-based therapies are driving growth in urothelial cancer markets, with Zusduri showing strong early commercial performance and unique non-surgical positioning. Next-gen products like UGN-103 promise operational efficiencies and extended IP, while strategic collaborations and a robust cash position support future expansion.
UroGen Pharma Transcript: Wells Fargo 21st Annual Healthcare Conference
ZUSDURI's launch in non-muscle invasive bladder cancer has driven significant growth, supported by a strong value proposition and expanding prescriber base. Next-generation products and pipeline expansion, including UGN-103, UGN-104, and UGN-501, aim to sustain momentum and broaden the addressable market.
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and spec...
UroGen Pharma to Present at Upcoming Investor Conferences
PRINCETON, N.J., Sept. 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies
IntraGel secures up to $7 million equity investment from UroGen® to advance the Phase 2 clinical study of TumoCure, for the treatment of advanced head and neck cancer UroGen gains access to IntraGel's...
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline
Collaboration grants UroGen a research license and exclusive options to license and develop up to three oncology products utilizing IntraGel's proprietary SRGel platform Agreement also includes an exc...
UroGen Pharma submits UGN-103 NDA to FDA
UroGen Pharma (URGN) announced the submission of a new drug application, or NDA, to the FDA for its investigational drug UGN-103 for intravesical solution. UGN-103 is a next-generation mitomycin formu...